Skip to main content
. Author manuscript; available in PMC: 2017 Feb 15.
Published in final edited form as: Clin Cancer Res. 2015 Oct 5;22(4):948–960. doi: 10.1158/1078-0432.CCR-15-0379

Figure 6.

Figure 6

Synergy between crizotinib and topo/cyclo is abrogated in ALK mutated cells with stable knockdown of p53. Cells were treated with shRNA lentivirus against p53 or a copGFP control and levels of p53 knockdown compared to the GFP control are shown for (A) NB-1643 and (B) SH-SY5Y cells. The GFP control infected cells, and two different shRNA infected cells, were treated with vehicle, crizotinib, topotecan plus 4-HC, or crizotinib and topotecan/4-HC and synergy was analyzed by DIMSCAN. Survival curves and CI vs. Fa plots are shown for NB-1643 (C) and (D) and SH-SY5Y (E) and (F).